Tubulointerstitial
inflammation plays an important role in the progression of
diabetic nephropathy (DN), and tubular epithelial cells (TECs) are crucial promoters of the inflammatory cascade. Exchange
protein activated by cAMP (
Epac) has been shown to suppress the
angiotensin II (Ang-II)-induced release of inflammatory
cytokines in tubular cells. However, the role of
Epac in TEC-mediated tubulointerstitial
inflammation in DN remains unknown. We found that administering the
Epac agonist
8-pCPT-2'-O-Me-cAMP (8-O-cAMP) to db/db mice inhibited tubulointerstitial
inflammation characterized by macrophage infiltration and increased inflammatory
cytokine release and consequently alleviated tubulointerstitial
fibrosis in the kidney. Furthermore, 8-O-cAMP administration restored
CCAAT/enhancer binding protein β (C/EBP-β) expression and further upregulated the expression of Suppressor of
cytokine signaling 3 (SOCS3), while inhibiting p-STAT3, MCP-1,
IL-6, and TNF-α expression in the kidney cortex in db/db mice. And in vitro study showed that macrophage migration and MCP-1 expression induced by high
glucose (HG, 30 mM) were notably reduced by 8-O-cAMP in human renal proximal tubule epithelial (HK-2) cells. In addition, 8-O-cAMP treatment restored C/EBP-β expression in HK-2 cells and promoted C/EBP-β translocation to the nucleus, where it transcriptionally upregulated SOCS3 expression, subsequently inhibiting STAT3 phosphorylation. Under HG conditions,
siRNA-mediated knockdown of C/EBP-β or SOCS3 in HK-2 cells partially blocked the inhibitory effect of
Epac activation on the release of MCP-1. In contrast, SOCS3 overexpression inhibited HG-induced activation of STAT3 and MCP-1 expression in HK-2 cells. These findings indicate that
Epac activation via 8-O-cAMP ameliorates tubulointerstitial
inflammation in DN through the C/EBP-β/SOCS3/STAT3 pathway.